8th May 2025
Why the FDA animal testing phase-out for monoclonal antibodies?
8th May 2025
Microphysiological systems for mAbs development: how do they address animal limitations?
1st May 2025
Blog
Microphysiological systems for mAbs development: how do they address animal limitations?
1st May 2025
Blog
Why the FDA animal testing phase-out for monoclonal antibodies?
29th April 2025
Press releases
NIH to prioritize human-based research technologies & reduce animal use in research
24th April 2025
How OOC can improve in vitro to in vivo translatability of preclinical data
24th April 2025
Press releases
CN Bio and Pharmaron establish long-term strategic partnership to develop OOC technologies on a global R&D platform
10th April 2025
Developments in Drug Discovery
10th April 2025
Organ-on-a-chip: a modernized toolbox for drug discovery challenges
10th April 2025
PhysioMimix® bioavailability assay kit: Human 18 for simultaneous oral and intravenous in vitro bioavailability profiling
10th April 2025
PhysioMimix® DILI assay kit: Human 24 for deeper mechanistic hepatotoxicity insights
10th April 2025
Press releases
FDA’s plan to phase out animal testing requirement for monoclonal antibodies and other drugs with more human-relevant methods
7th April 2025
Advancing oligonucleotide therapies with liver-on-a-chip models
4th April 2025
A liver microphysiological system to study the delivery and efficacy of oligonucleotide-based therapeutics
27th March 2025
Harnessing liver-on-a-chip models for drug safety
27th March 2025
Advancing oligonucleotide therapies with liver-on-a-chip models
19th March 2025
Oligonucleotide delivery
13th March 2025
Addressing the challenges of developing new modality drugs
11th March 2025
Sign up for our newsletter
6th March 2025
Multimodal imaging of a liver-on-a-chip model using labelled and label-free optical microscopy techniques
28th February 2025
Validating a human dual-organ MPS for better drug (ADME) studies
27th February 2025
The Rise of Oligonucleotide Therapeutics: Overcoming ADMET Development Challenges with Human-Centric Approaches
26th February 2025
How Organ-on-a-chip can reduce DILI risk in drug development
25th February 2025
Evaluating a human DILI assay kit’s ability to unlock complex mechanisms of toxicity
24th February 2025
Blog
The Rise of Oligonucleotide Therapeutics: Overcoming ADMET Development Challenges with Human-Centric Approaches
4th February 2025
PhysioMimix® DILI Assay Kit
4th February 2025
Press releases
CN Bio launches PhysioMimix® DILI assay kit: Human 24
30th January 2025
Countdown
13th January 2025
Press releases
CN Bio signs strategic partnership with Primetech Corporation to establish distribution channel for OOC solutions in Japan
17th December 2024
MPS World Summit 2025
16th December 2024
Vox Pop Pharma – companies keen to find alternatives to animal testing – read their views
16th December 2024
Next Generation Drug Discovery: Bridging the Gap with Organ-on-a-Chip Technology
12th December 2024
Distributor support & maintenance
12th December 2024
Your PhysioMimix support packages
10th December 2024
A Gut/Liver microphysiological system for profiling human oral bioavailability
5th December 2024
WORD+ 2025
29th November 2024
Blog
Evaluating Caco-2 cell’s gold-standard status in absorption, permeability and bioavailability Studies: Are Their Limitations Justified?
29th November 2024
Evaluating Caco-2 cell’s gold-standard status in absorption, permeability and bioavailability Studies: Are Their Limitations Justified?
19th November 2024
Go/No-Go
18th November 2024
Team Q&A
Meet the CN Bio team – Oliver Culley
14th November 2024
Press releases
CN Bio launches PhysioMimix Bioavailability assay kit: Human 18
12th November 2024
A Gut/Liver microphysiological system for profiling human oral bioavailability
5th November 2024
PhysioMimix® Bioavailability Assay Kit
18th October 2024
User Group Meeting 2024 – Recap
18th October 2024
Blog
User Group Meeting 2024 – Recap
17th October 2024
Organ-on-a-chip technology
9th October 2024
Go/No-Go
8th October 2024
ACT 2024
4th October 2024
Lost in Translation
26th September 2024
Drug Discovery 2024
6th September 2024
Lost in Translation
23rd August 2024
Team Q&A
Meet the CN Bio team – Uranbileg Myagmarsuren
14th August 2024
Bridging the gap
24th July 2024
6 Challenges in ADME Drug Development
24th July 2024
Blog
6 Challenges in ADME Drug Development
24th July 2024
Organ-on-a-Chip: Big Questions Surrounding Regulation and the Roadmap to Broad Adoption
23rd July 2024
Liver-on-chip model and application in predictive genotoxicity and mutagenicity of drugs
10th July 2024
SOT 2025
10th July 2024
Team Q&A
Meet the CN Bio team – Joanna Michalowska
3rd July 2024
Defining validation criteria for a primary jejunum and primary hepatocyte dual-organ MPS
2nd July 2024
How in vitro human Gut/Liver models increase confidence in ADME estimations before human trials
2nd July 2024
Organ-on-a-chip adoption: The roadmap to broader use
28th June 2024
Blog
How in vitro human Gut/Liver models increase confidence in ADME estimations before human trials
28th June 2024
Blog
Organ-on-a-chip adoption: The roadmap to broader use
28th June 2024
Developed the model, built the assay, now a focus on THROUGHPUT! The Liver-48, designed for industry adoption
27th June 2024
Press releases
CN Bio appoints Lydia Seymour as VP People and Culture to further strengthen leadership team
21st June 2024
Search
17th June 2024
How Organ-on-a-Chip Addresses R&D Challenges
13th June 2024
Developing a translational biomarker panel for use in pre-clinical advanced in vitro studies of Non-alcoholic steatohepatitis
13th June 2024
Blog
Global Fatty Liver Day 2024: How Organ-on-a-Chip Addresses R&D Challenges
10th June 2024
DMDG 2024
7th June 2024
Team Q&A
Blog
Meet the CN Bio team -Dr. Dharaminder Singh
22nd May 2024
About us – draft
7th May 2024
Careers Fair
30th April 2024
Understanding the mechanism of toxicity: OOC’s crucial role
23rd April 2024
Press releases
CN Bio raises $21 million USD in first close of Series B investment round
19th April 2024
Blog
Understanding the mechanism of toxicity: OOC’s crucial role
16th April 2024
User Group Meeting 2024
15th April 2024
Press releases
CN Bio selected for NC3R’s SensOoChip Challenge to develop advanced Heart-on-a-Chip
20th March 2024
Lab Essentials Competition
15th March 2024
EUROTOX 2024
14th March 2024
ESTIV 2024
26th February 2024
Connecting the gut and liver
20th February 2024
SOT 2024
30th January 2024
Press releases
CN Bio appoints Joseph Parisi as US Director of Sales
23rd January 2024
Press releases
CN Bio and Altis Biosystems partnership
18th January 2024
Connecting the human intestine and liver
18th January 2024
MPS World Summit 2024
11th January 2024
Gut/Liver-on-a-chip
8th January 2024
Harnessing Microphysiological Systems to Bring Humanized Processes to ADME and Bioavailability Studies
11th December 2023
Careers
6th December 2023
CONTACT FORM TEST
4th December 2023
Press releases
PhysioMimix data supports Inipharm’s INI-822 for metabolic liver disease treatment
29th November 2023
Beyond hepatotoxicity red flags
28th November 2023
Set yourself up for success with organ-on-a-chip
28th November 2023
Normalization of organ-on-a-chip samples
23rd November 2023
Press releases
OBN Awards 2023 winner!
2nd November 2023
PhysioMimix Nash-in-a-box brochure
2nd November 2023
Press releases
CN Bio appoints Neil Rumbelow as Director of Product Development
19th October 2023
Business
CN Bio showcased in PwC UK’s ‘Life Sciences Future 50’ report 2023
10th October 2023
Taking organoids to the next level
5th October 2023
Blog
Taking organoids to the next level
7th September 2023
A guide to pre-validating cells for use in Organ-on-a-chip assays
5th September 2023
Blog
A guide to pre-validating primary cells for use in Organ-on-a-chip assays
5th September 2023
Press releases
CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems
30th August 2023
Press releases
CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer
26th July 2023
Recreating Life in the Lab: How Predictive Human Organ Models are Transforming the Efficiency of Drug Discovery
26th July 2023
Tech Blast | Organ-on-a-chip technologies
17th July 2023
Summary report: Insights into new preclinical non animal models
17th July 2023
Full report: Insights into new preclinical non animal models
17th July 2023
What is organ-on-a-chip technology?
17th July 2023
Top tips for integrating organ-on-a-chip technology into your workflow
20th June 2023
Alveolar and Bronchial Microphysiological Systems for respiratory infection research and therapeutics evaluation
20th June 2023
Organ-on-a-chip Contract Research Services Brochure
9th June 2023
A primary jejunum and primary hepatocyte multi-organ MPS
6th June 2023
Press releases
CN Bio appoints Dr. Samantha Macro as Chief Financial Officer
25th May 2023
Product Recycling
3rd May 2023
Advanced pathophysiology mimicking lung models for accelerated drug discovery
3rd May 2023
Characterization of the effect of primary human hepatocytes (PHH) lots of functions in CN Bio Innovations Liver-Chip using acetaminophen
20th March 2023
Immune-mediated DILI – Predicting the unpredictable!
16th March 2023
Blog
Immune-mediated DILI – Predicting the unpredictable!
14th March 2023
Press releases
CN Bio appoints Deepak Singh as Vice President of Sales and Marketing
27th February 2023
Introducing PhysioMimix HT
27th February 2023
PhysioMimix Organ-on-a-Chip Brochure
27th February 2023
PhysioMimix Single-organ HT system
27th February 2023
Press releases
CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System
17th February 2023
Organ-on-a-chip provides preclinical safety toxicologists with the tools to combat drug attrition
10th February 2023
Organ-on-a-chip models in drug development
2nd February 2023
In Vitro Non-Alcoholic Steatohepatitis (NASH) Services
27th January 2023
PhysioMimix® Liver plates
27th January 2023
PhysioMimix® Multi-chip plates
27th January 2023
PhysioMimix® OOC Microphysiological Systems
17th January 2023
About CN Bio…
17th January 2023
Press releases
The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system
11th January 2023
The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, what can be embraced in its place?
9th January 2023
Blog
The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place.
4th January 2023
Normalization of organ-on-a-Chip samples for mass spectrometry based proteomics and metabolomics via Dansylation-based assay
19th December 2022
Press releases
CN Bio appoints Dr Paul Brooks as Chief Executive Officer
3rd December 2022
Modelling the intestine-liver axis: The role of FXR agonists in a multi-organ microphysiological system model of non-alcoholic fatty liver disease
28th November 2022
The Human Touch
28th November 2022
ADME Studies: Determining Promising Drug Compounds
31st October 2022
The Dash for NASH
21st October 2022
How to Keep Breathing – The Future of Inhaled Medication Testing
21st October 2022
PhysioMimix Multi-organ System Animation
30th September 2022
Evaluation of in vitro human alveolar and bronchial microphysiological systems to predict the permeability and absorption of inhaled pulmonary medications
10th September 2022
Human liver microphysiological system for predicting the drug-induced liver toxicity of differing drug modalities
9th September 2022
Microphysiological system for studying fatty liver disease and its impact on drug-induced liver injury
30th August 2022
Accessibility
30th August 2022
Cookie policy
15th August 2022
Application of a gut–liver-on-a-chip device and mechanistic modeling to the quantitative in vitro pharmacokinetic study of mycophenolate mofetil
15th August 2022
Leadership team
4th August 2022
Turning to Organ-on-a-Chip Studies for the Future of Drug Discovery
25th July 2022
Pros and cons of preclinical models of Non-Alcoholic Steatohepatitis
25th July 2022
In Focus: Modeling NASH disease – organ-on-a-chip technologies
25th July 2022
Every Breath You Take
25th July 2022
Organ-on-a-Chip Models of Fatty Liver Disease
19th July 2022
Press releases
CN Bio opens new laboratory facilities to extend Organ-on-a-chip contract research services capabilities
5th July 2022
PhysioMimix® multi-chip plates
27th June 2022
MPS World Summit Round-up
27th June 2022
Blog
MPS World Summit round-up 2022
15th June 2022
Biotechnology: Bringing New Treatments to Market
14th June 2022
Drug Discoveries Without Animal Testing
6th June 2022
Why two organs are better than one
6th June 2022
Alveolar and bronchial human microphysiological systems for use in respiratory infection research and therapeutics evaluation
6th June 2022
Primary vs. Stem-Like Cells in 3D Cultures
25th May 2022
A Breath of Fresh Air
24th May 2022
Press releases
CN Bio appoints Dr Paul Brooks as Chief Business Officer
11th May 2022
Normalization of organ-on-a-chip samples for mass spectrometry based proteomics and metabolomics via dansylation-based assay
6th May 2022
Harnessing the power of multimodal imaging to explore ASO distribution in cells, complex in vitro models and tissue
5th May 2022
PhysioMimix® NASH-in-a-box
26th April 2022
Press releases
CN Bio introduces PhysioMimix NASH ‘in-a-box’ reagent kit
6th April 2022
Careers in Biotech
24th March 2022
Terms and Conditions
24th March 2022
Regulatory
23rd March 2022
The lung in crisis
23rd March 2022
Blog
The lung in crisis: fighting back against pathogens, infections and inflammation with predictive in vitro lung models that accelerate drug discovery
17th March 2022
Lung-on-a-chip
5th March 2022
Animal Models and Microfluidic Tools with a Human Touch
5th March 2022
New Model Will Support Drug Discovery for Liver Disease NASH
1st March 2022
CN is believing
25th February 2022
Opinionated Science: What is Body-on-a-Chip Technology
24th February 2022
Debunking the 9 Myths of Organ-on-a-Chip Technology
24th February 2022
Blog
Debunking the 9 myths of Organ-on-a-chip technology
6th February 2022
Assessing drug-induced liver injury using a sensitive and selective human liver microphysiological system and clinical biomarkers
31st January 2022
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
25th January 2022
Exploration and Application of a Liver-on-a-Chip Device in Combination with Modelling and Simulation for Quantitative Drug Metabolism Studies
1st January 2022
ORGAN-ON-A-CHIP – A Novel Way to Accurately Test Delivery of Non-Standard Formulations
1st January 2022
A pressing Need for Accurate Preclinical Models of Metabolic Disease
18th December 2021
Multiorgan microphysiological systems as tools to interrogate interorgan crosstalk and complex diseases
15th December 2021
β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development
13th December 2021
Predicting Drug Bioavailability with the Modern-Day Toolkit
7th December 2021
De-risking drug-induced liver injury through the predictive power of organ-on-a-chip
7th December 2021
Improved prediction of oral bioavailability using a gut-liver microphysiological system
7th December 2021
Blog
De-risking drug-induced liver injury through the predictive power of organ-on-a-chip
1st December 2021
Reduce, Refine… Replace?
1st December 2021
Press releases
PhysioMimix® Multi-Organ Microphysiological System selected by The Scientist as a ‘Top 10 Innovation 2021′
22nd November 2021
From Dose to Circulation: Determination of Drug Oral Bioavailability Using a Gut-Liver Microphysiological System
10th November 2021
Blog
De-risking pre-clinical drug-induced liver injury with organ-on-a-chip
9th November 2021
Press releases
CN Bio and iiCON announce COVID-19 research collaboration
6th November 2021
Drug metabolism in a gut-liver microphysiological system
30th October 2021
Hype or hope – microphysiological systems?
9th October 2021
Fighting Toxic Chemicals: Evaluating the Safety of Cobinamide as a Neutralizing Agent
5th October 2021
Press releases
CN Bio expands service offering to support oncology drug discovery
22nd September 2021
Making a difference with disruptive organ-on-a-chip technology
15th September 2021
Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system
9th September 2021
Predictive DILI Models: Human Liver Microphysiological System for Studying Acute and Chronic Drug-Induced Liver Toxicity
1st September 2021
The economic impact of the UK’s New Approach Methodologies sector
16th August 2021
Organ-on-chip applications in drug discovery: an end user perspective
13th August 2021
Predicting human drug permeability with a gut microphysiological system
11th August 2021
Microphysiological systems of the human liver, gut and linked liver-gut, to assess human drug absorption, metabolism and bioavailbility
9th August 2021
Liver-on-Chip and In Silico Modeling for Quantitative Drug Metabolism Studies
30th July 2021
Liver-on-a-chip
28th July 2021
PhysioMimix® support packages
28th July 2021
In vitro ADME services
28th July 2021
Pulmonary infection
28th July 2021
Hepatitis B
28th July 2021
Drug-induced liver injury (DILI)
28th July 2021
Metabolic dysfunction-associated steatohepatitis (MASH) in vitro
28th July 2021
Immune-mediated liver injury
28th July 2021
Drug bioavailability
28th July 2021
Drug metabolism in vitro
28th July 2021
Drug absorption
28th July 2021
ADME in vitro models
28th July 2021
PhysioMimix® Organ-on-a-chip models
28th July 2021
PhysioMimix® 3D validated cells
28th July 2021
PhysioMimix® dual-organ plate
28th July 2021
PhysioMimix® Barrier plate
28th July 2021
PhysioMimix® Liver plate
27th July 2021
Press releases
CN Bio licenses human gut organ microbiome modelling tool from MIT and Northeastern University
19th July 2021
Press releases
Lonza and CN Bio announce distribution agreement
15th July 2021
Blog
Of Mice and Men – Will human organ-on-a-chip disease models replace animal use?
29th June 2021
Press releases
CN Bio’s PhysioMimix® adopted by King’s College London to investigate chronic liver disease
24th June 2021
Business
Cell4Pharma enters supply agreement with CN Bio
9th June 2021
2D, or Not 2D
27th May 2021
IP-10 (CXCL10) Can Trigger Emergence of Dormant Breast Cancer Cells in a Metastatic Liver Microenvironment
24th May 2021
Gut-Liver Physiomimetics Reveal Paradoxical Modulation of IBD-Related Inflammation by Short-Chain Fatty Acids
11th May 2021
The characterisation of a human two organ on a chip ( lung-Liver) system
9th May 2021
Pathologically Scarred by Fibrosis: How To Model and Quantify Human NASH in a Microphysiological System
5th May 2021
Press releases
CN Bio FDA collaboration expanded
21st April 2021
NAFLD vs MAFLD: could a name change impact the progression of liver disease research?
21st April 2021
Blog
NAFLD vs MASLD: could a name change impact the progression of liver disease research?
9th April 2021
Towards a Body-on-a-Chip: The Value of Multi-Organ MPS for Human-Relevant Drug Assessment
17th March 2021
Press releases
Introducing the PhysioMimix® OOC Multi-Organ Microphysiological System
9th March 2021
Engineering Mucosal Barriers
1st March 2021
Press releases
CN Bio awarded Innovate UK grant to develop single and multi-organ models for COVID-19 research
17th February 2021
Blog
Flowing to the beat of your heart
17th February 2021
Flowing to the Beat of Your Heart
11th February 2021
Multi-Organ in vitro organ-on-chip models for intestinal drug absorption and metabolism
11th February 2021
Gut-liver organ-on-a-chip combined with in silico modeling as a promising tool for investigation of mycophenolate mofetil pharmocokinetics
10th February 2021
Safety toxicology
9th February 2021
A Microphysiological Model of Metastatic Progression
1st February 2021
3D Cell Based Assays: Tips for Success
28th January 2021
Sitting down with… CN Bio
28th January 2021
Events
27th January 2021
How a novel in vitro Liver-on-a-Chip model of fatty liver disease is being used to help prevent a global healthcare crisis.
27th January 2021
Blog
How a novel in vitro Liver-on-a-chip model of fatty liver disease is being used to help prevent a global healthcare crisis.
15th January 2021
Primary human colonic mucosal barrier crosstalk with super oxygen-sensitive Faecalibacterium prausnitzii in continuous culture
11th January 2021
Press releases
CN Bio’s PhysioMimix® technology receives FDA recognition
11th January 2021
Life in the Fastlane
11th January 2021
Blog
Life in the fastlane
9th January 2021
Testing on Humans
31st December 2020
Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism and accumulation
15th December 2020
Press releases
CN Bio and the University of Melbourne collaborate to advance therapies for respiratory complications in recovered COVID-19 patients
9th December 2020
The Rhythm of Life
9th November 2020
A Regulators Viewpoint
27th October 2020
Press releases
CN Bio to provide drug metabolism and safety toxicity testing services
21st October 2020
Predicting the future: humanised drug evaluation testing using organ-on-a-chip technology
16th October 2020
PhysioMimix® consumables
16th October 2020
Drug-induced liver injury (DILI) in vitro services
16th October 2020
In vitro Metabolic dysfunction-associated-steatohepatitis (MASH) Services
9th October 2020
Go with the Flow
9th September 2020
The Scars of Fat
8th September 2020
Press releases
CN Bio and Imperial College London Collaboration
3rd September 2020
Cell-Based Assays in 2D and 3D
15th August 2020
PhysioMimix Single-organ System Animation
9th August 2020
An Introduction to Organ‑On‑a‑Chip
5th August 2020
Press releases
CN Bio makes key senior appointments to support international commercial development
13th July 2020
PhysioMimix® OOC Microphysiological Systems
13th July 2020
In vitro contract research services
9th June 2020
Press releases
CN Bio and Cambridge University identify novel regulatory pathway driving NASH
8th June 2020
Bone morphogenetic protein 8B promotes the progression of Non-Alcoholic Steatohepatitis
1st June 2020
Microphysiological Systems Emerging as Powerful Tools for Drug Discovery
30th April 2020
Disease modeling
30th April 2020
Contact
30th April 2020
News
30th April 2020
Organ-on-a-Chip Resources
30th April 2020
Organ-on-a-chip applications
8th April 2020
About us
2nd March 2020
Press releases
CN Bio Innovations raises $9 million USD (c. £6.9 million GBP)
27th January 2020
Privacy statement
12th December 2019
Home
13th November 2019
A Microphysiological System for Studying Non-alcoholic Steatohepatitis
11th November 2019
Press releases
NASH drug discovery service launched at AASLD
11th August 2019
Comparing an in vitro Organ-on-Chip model of Non-Alcoholic Steatohepatitis to murine models and liver tissue from patients
1st May 2019
Press releases
Sydney’s AXT offers Organ-on-Chip systems in Asia Pacific region
28th February 2019
Press releases
CN Bio to bring 10 organs together on a chip
19th February 2019
“Liver-on-a-Chip” Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
22nd November 2018
Press releases
PhysioMimix® Human 3D Cell Culture wins Lab Innovation 2018 Award
11th August 2018
The PNPLA3 I148 variant enhances the disease phenotype of hepatic stellate cells in an in vitro model of non-alcoholic fatty liver disease
19th July 2018
Press releases
CN Bio Innovations’ Board names David Hughes as next Chief Executive Officer
23rd May 2018
Press releases
CN Bio launches PhysioMimix benchtop Human-Body-on-a-Chip device
1st May 2018
Media Coverage
Radio 4’s PM features CN Bio Human Organ-on-Chips
14th March 2018
Press releases
CN Bio and MIT announce 10 Organ-On-chip platform: Nature Scientific Reports
14th March 2018
Interconnected microphysiological systems for quantitative biology and phamarcology studies
2nd March 2018
Business
CN Bio MicroMix to be featured at AACR
23rd February 2018
Perfused human hepatocyte microtissues identify reactive metabolite-forming and mitochondria-perturbing hepatotoxins
22nd February 2018
Business
PharmaVentures interview: Will Organ-on-Chip technology provide the data regulators need in the future?
15th February 2018
Media Coverage
Hepatitis B research using CN Bio Organ-on-chips published in Nature Communications
14th February 2018
3D microfluidic liver cultures as a physiological preclinical tool for hepatitis B virus infection
15th December 2017
Business
R&D 100 Award won by Vanderbilt team for tech being developed with CN Bio
1st November 2017
Press releases
CN Bio Innovations announces research collaboration with AstraZeneca to validate a new in vitro tool to predict optimised drug dosing regimens for multi-drug therapies
26th October 2017
Press releases
FDA signs collaborative agreement with CN Bio Innovations to use Organs-on-Chips to improve drug development and evaluation
11th October 2017
Press releases
Innovate UK awards grant to CN Bio Innovations and AstraZeneca to use Organs-on-Chips to evaluate the use of existing drugs to treat fatty liver disease
9th October 2017
Press releases
CN Bio Innovations announces licence of platform microfluidics technologies from Vanderbilt University
27th July 2017
Integrated gut and liver microphysiological systems for quantitative in vitro pharmacokinetics studies
1st July 2017
Integrated assessment of diclofenac biotransformation, pharmacokinetics and omics-based toxicity in a 3D human liver-immunocompetent co-culture system
1st July 2017
Integrated gut/liver microphysiological systems elucidates inflammatory inter-tissue crosstalk
11th June 2017
Fully human in vitro gut-liver model of non-alcoholic steatohepatitis
11th May 2017
Microphysiological systems for studying interactions between the liver, gut and immune system
5th April 2017
Press releases
CN Bio Innovations announces license of worldwide rights to Hepatitis B programme from Bristol-Myers Squibb
1st March 2017
Multi-functional scaling methodology for translational pharmacokinetic and pharmacodynamic applications using integrated MPS
3rd February 2017
Media Coverage
Huffington Post features CN Bio
1st January 2017
Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three-Dimensional Human Liver Microphysiological System
19th December 2016
Modeling Therapeutic Antibody-Small Molecule Drug-Drug Interactions Using a Three-Dimensional Perfusable Human Liver Coculture Platform
30th November 2016
Media Coverage
CN Bio featured on the Discovery Channel
15th November 2016
Press releases
Dr Emma Sceats of organ-on-a-chip firm CN Bio Innovations wins Innovate UK’s infocus Women in Innovation award
11th August 2016
Three-dimensional human cell culture model for studying Non-Alcoholic Fatty Liver Disease
13th June 2016
Business
MIT and CN Bio to showcase world’s first 7 organ “Human-on-a-Chip” at Organ-On-Chip congress
6th June 2016
Business
CN Bio Sponsors the Organ-On-Chip world congress in Boston
11th May 2016
Identification And Evaluation Of Patient Serum Isolates As A Source Of Inoculum For 3D in Vitro Cell Culture: A Tool For Drug Discovery
4th January 2016
Business
CN Bio appoints Emma Sceats as CEO
2nd November 2015
Business
Imperial College London to present HBV data on CN Bio immune-competent liver model at AASLD The Liver Meeting
5th October 2015
Quantitative systems pharmacology approaches applied to MPS: Data interpretation and Multi-MPS integration
14th August 2015
Business
CN Bio appoints Dr David Hughes to board of directors
11th August 2015
Business
CN Bio Innovations features in Al Jazeera documentary “The Cure”
1st July 2015
Metabolite profiling and pharmacokinetic evaluation of hydrocortisone in a perfused 3D human liver bioreactor
12th June 2015
Business
CN Bio Innovations announces deal with sixth pharmaceutical collaborator in 2015 and features in The Economist
2nd June 2015
Press releases
CN Bio Innovations announces research collaboration with Alnylam
27th May 2015
Business
CN Bio Innovations announces LiverChip research study with leading pharmaceutical company
11th May 2015
Three-dimensional perfused cell culture enhances the infectability of primary human hepatocytes with Hepatitis B virus
29th April 2015
Media Coverage
Bloomberg and Businessweek feature CN Bio Innovations’ LiverChip Platform
21st April 2015
Business
CN Bio Innovations announces Hepatitis B research collaboration with leading pharmaceutical company
19th March 2015
Business
CN Bio announces research collaboration with antisense discovery pioneers Isis Pharmaceuticals
2nd March 2015
Press releases
CN Bio announces research collaboration with gene silencing specialist Benitec Biopharma
23rd January 2015
Morphological behaviour and metabolic capacity of cryopreserved human primary hepatocytes cultivated in a perfused multiwell device
12th January 2015
Press releases
CN Bio announces opening of new Biosafety Level 3 facility
8th January 2015
Addressing the Challenges of Low Clearance in Drug Research
17th November 2014
Business
CN Bio hosts popular Investigator Meeting and presents new HBV data at AASLD 2014
28th October 2014
Business
NIH Director highlights LiverChip in Compton Lecture
17th September 2014
Business
TSB Funds New Research by CN Bio into Fatty Liver Disease
2nd September 2014
Press releases
Imperial College London to present first public HBV data from CN Bio in vitro liver model
28th July 2014
Press releases
CN Bio Innovations marks World Hepatitis Day by signing research agreement with Imperial College London
4th April 2014
Business
CN Bio hires Director of Licensing
26th March 2014
Business
Liver disease to become a bigger killer than heart disease or cancer
10th February 2014
Press releases